Sanofi has agreed to acquire vaccine maker Dynavax Technologies in an all-cash deal worth $2.2 billion in total equity value.

The biotech sector has been a disaster for investors over the past five years going by a 14% decline compared to an 86% gain ...

William Blair has hand-picked its top five stock recommendations for 2026, selections that include three clinical-stage ...

Major U.S. stock indices closed higher Tuesday, with the Dow Jones Industrial Average up 0.16% at 48,442.41, the S&P 500 ...

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and ...

The bank's list of highest-conviction stock picks for 2026 spans numerous sectors and features names including Pepsi and GM.

Abivax (ABVX) stock leads biotech M&A prospects for 2026 while Madrigal Pharmaceuticals (MDGL) trails, according to a survey ...

Now, it’s worth noting Stock Advisor’s total average return is 985 % — a market-crushing outperformance compared to 195% for ...

Abivax SA soared about 1,300% after successful trial results for a bowel disease drug, Argenx SE was added to the elite Euro ...